Zobrazeno 1 - 10
of 18 800
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Garth W. Strohbehn, Robert Holleman, Jennifer Burns, Mandi L. Klamerus, Michael J. Kelley, Eve A. Kerr, Nithya Ramnath, Timothy P. Hofer
Publikováno v:
JAMA oncology. 8(11)
ImportanceExtended-interval dosing of pembrolizumab (400 mg every 6 weeks) was approved by US Food and Drug Administration (FDA) in April 2020 as an alternative to standard-interval dosing (200 mg every 3 weeks). Extended-interval dosing may enhance
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Charles Faselis, Joel A. Nations, Charity J. Morgan, Jared Antevil, Jeffrey M. Roseman, Sijian Zhang, Gregg C. Fonarow, Helen M. Sheriff, Gregory D. Trachiotis, Richard M. Allman, Prakash Deedwania, Qing Zeng-Trietler, Daniel D. Taub, Amiya A. Ahmed, George Howard, Ali Ahmed
Publikováno v:
JAMA Oncol
ImportanceThe US Preventive Services Task Force does not recommend annual lung cancer screening with low-dose computed tomography (LDCT) for adults aged 50 to 80 years who are former smokers with 20 or more pack-years of smoking who quit 15 or more y
Publikováno v:
Cancer Research and Treatment. 54:1030-1037
PurposeAlthough lung cancer incidences in female never-smokers have increased, few studies focus on explicit investigation. We aimed to investigate the relationship between long-term exposure to ambient particulate matter sized 10 μm or less in diam
Autor:
Takahiro Fukushima, Yoshitaka Oyamada, Shinnosuke Ikemura, Shigenari Nukaga, Takashi Inoue, Daisuke Arai, Keiko Ohgino, Aoi Kuroda, Kota Ishioka, Fumio Sakamaki, Yusuke Suzuki, Hideki Terai, Hiroyuki Yasuda, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima
Publikováno v:
Clinical Lung Cancer. 23:532-541
The optimal treatment for advanced non-small cell lung cancer (NSCLC) in very elderly patients is unclear. We aimed to evaluate their treatment in real-world clinical practice and identify suitable therapy that can improve their prognosis.The medical
Autor:
Taro Yoneda, Takashi Sone, Hayato Koba, Kazuhiko Shibata, Junya Suzuki, Mayuko Tani, Masaru Nishitsuji, Koichi Nishi, Takafumi Kobayashi, Hiroki Shirasaki, Tomoyuki Araya, Toshiyuki Kita, Kazumasa Kase, Kenta Yamamura, Nanao Terada, Shingo Nishikawa, Yuichi Tambo, Hideharu Kimura, Kazuo Kasahara
Publikováno v:
Clinical Lung Cancer. 23:467-476
Immune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with ICI has been fo
Autor:
Hasmeena Kathuria, Adrian Gunawan, Matthew Spring, Sara Aijaz, Vinson Cobb, Carmel Fitzgerald, Cornelia Wakeman, Jinesa Howard, Mary Clancy, Alexis Gallardo Foreman, Ve Truong, Carolina Wong, Katrina Steiling, Karen E. Lasser, Katia Bulekova, Renda Soylemez Wiener
Publikováno v:
Cancer Causes & Control. 33:1373-1380
Medicare requires tobacco dependence counseling and shared decision-making (SDM) for lung cancer screening (LCS) reimbursement. We hypothesized that initiating SDM during inpatient tobacco treatment visits would increase LCS among patients with barri
Publikováno v:
Nutrition and Cancer. 74:3623-3633
This study aimed to quantitatively identify the prognostic and clinicopathological value of the geriatric nutritional risk index (GNRI) in non-small cell lung cancer (NSCLC) through a meta-analysis. The electronic databases PubMed, Web of Science, Em
Autor:
Christian Lang, Felix Egger, Mir Alireza Hoda, Alessandro Saeed Querner, Bence Ferencz, Victor Lungu, Robert Szegedi, Levente Bogyo, Klara Torok, Felicitas Oberndorfer, Thomas Klikovits, Anna Schwendenwein, Kristiina Boettiger, Ferenc Renyi-Vamos, Konrad Hoetzenecker, Karin Schelch, Zsolt Megyesfalvi, Balazs Dome
Publikováno v:
Lung Cancer. 169:40-46
The prognostic value of lymphocyte-to-monocyte ratio (LMR) has already been evaluated in a wide range of malignancies including patients with non-surgically managed small cell lung cancer (SCLC). However, the impact of LMR on survival in surgically t